Drugs / OligoG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01465529 | May 2011 → Oct 2013 | cystic fibrosis | AlgiPharma AS | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01991028 | Apr → Sep 2014 | cystic fibrosis | BDD Pharma Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03822455 Comparator | May 2019 → Mar 2020 | cystic fibrosis | AlgiPharma AS | Terminated | No outcome recorded |
| Phase 2/3 | NCT03698448 Comparator | Sep 2021 → Oct 2022 | cystic fibrosis | AlgiPharma AS | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-10-30 | AlgiPharma AS | Results AlgiPharma at Partnership Opportunities in Drug Delivery (PODD) Conference 2025, Boston, USA algipharma.com ↗
Our data demonstrate how AlgiPharma’s technology enhances oral bioavailability and improves mucus translocation for biologics and lipid nanoparticles, opening new frontiers in drug delivery and therapeutic design. |
| 2022-03-01 | AlgiPharma AS | Results AlgiPharma Study Published on Potentiation of Colistin. algipharma.com ↗
Addition of alginate oligosaccharide (OligoG CF-5/20) significantly improved colistin diffusion by 3.7 times through mucin-rich AS medium (at 48 h; p < 0.05). |
| 2022-02-01 | AlgiPharma AS | Results AlgiPharma Phase 2 Burkholderia Study Published. algipharma.com ↗
Of 14 subjects completing the study, 8 showed a mean decrease in total bacterial CFU’s (0.82 log10) after OligoG treatment. |
| 2016-02-24 | AlgiPharma AS | Regulatory AlgiPharma granted Orphan Drug designation by FDA algipharma.com ↗
AlgiPharma was granted Orphan Drug designation by the FDA for its sodium alginate oligosaccharide, OligoG in the treatment of cystic fibrosis (CF). |
| 2013-04-16 | AlgiPharma AS | Results The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms algipharma.com ↗
Rheology demonstrated that increasing clinically relevant concentrations of OligoG (<10%) were associated with an increasing phase angle (δ) over a wide range of frequencies (0.1-10 Hz). |
| 2012-08-26 | AlgiPharma AS | Results Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics algipharma.com ↗
OligoG increased (up to 512-fold) the efficacy of conventional antibiotics against important MDR pathogens, including Pseudomonas, Acinetobacter, and Burkholderia spp., appearing to be effective with several classes of antibiotic (i.e., macrolides, β-lactams, and tetracyclines). |
| 2011-04-01 | AlgiPharma AS | Regulatory AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis algipharma.com ↗
AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. |
| 2010-01-05 | AlgiPharma AS | Results AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases algipharma.com ↗
OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. |
| 2007-09-11 | AlgiPharma AS | Regulatory AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment algipharma.com ↗
AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OligoG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01991028 ↗ |
| Known as | OligoG CF-5/20 | “The alginate oligosaccharide OligoG CF-5/20 dry powder for inhalation (OligoG DPI) represents a novel therapeutic approach for patients with cystic fibrosis.” NCT03822455 ↗ |
| Modality | Other / unclassified | “Alginate Oligosaccharide (OligoG)” NCT01465529 ↗ |
| Route | Inhaled | “inhaled OligoG in CF subjects” NCT01465529 ↗ |